Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alosetron.

J A Balfour1, K L Goa, C M Perry

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand.

Drugs
|April 25, 2000
PubMed
Summary
This summary is machine-generated.

Alosetron, a serotonin 5-HT3 antagonist, effectively manages irritable bowel syndrome (IBS) by reducing pain and improving colon function. It was most beneficial for women with diarrhea-predominant IBS, though constipation was a common side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Levetiracetam.

CNS drugs·2013
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Neuroscience

Background:

  • Irritable bowel syndrome (IBS) is a common gastrointestinal disorder.
  • Serotonin 5-HT3 receptors play a role in visceral sensation and motility.
  • Alosetron is a selective serotonin 5-HT3 receptor antagonist.

Purpose of the Study:

  • To evaluate alosetron for managing irritable bowel syndrome (IBS).
  • To assess the efficacy and safety of alosetron in IBS patients.

Main Methods:

  • In vitro studies on guinea-pig neurons.
  • Animal models assessing visceral nociception and colonic compliance.
  • Clinical trials in human patients with IBS and healthy volunteers.

Main Results:

Related Experiment Videos

  • Alosetron inhibited 5-HT3 receptor-mediated depolarization in vitro.
  • It attenuated visceral nociception and increased colonic compliance in vivo.
  • Alosetron delayed colonic transit and increased fluid absorption, relieving pain in IBS patients, especially females with diarrhea-predominant IBS.

Conclusions:

  • Alosetron is effective in managing IBS symptoms, particularly abdominal pain and discomfort.
  • The drug demonstrates efficacy in improving colonic function and transit.
  • Constipation is the most frequent adverse event associated with alosetron use.